MET

MetLife

$95.67

-1.98%
Nov 20, 2026
Bobby Quantitative Model
MetLife, Inc. is one of the largest life insurers in the United States by assets, providing life insurance, annuities, employee benefits, and retirement solutions through six reporting segments: Group Benefits, Retirement and Income Solutions (RIS), Asia, Latin America, EMEA, and MetLife Investment Management. The company is a scale incumbent rather than a disruptor, distinguished by its leading group benefits franchise, a dominant Japan-centered Asia platform, and top-tier market positions in Mexico and Chile, with roughly 52% of adjusted earnings coming from its two U.S. businesses and about 25% from Asia. The current investor narrative centers on MetLife's transformation into a capital-return compounder: management has been aggressively shrinking its share count through buybacks while paying a dividend yielding above 3%, and the stock has re-rated sharply as earnings growth, favorable interest rates, and consistent execution have overcome the sector's historical "cheap for a reason" discount. Recent quarterly results showing strong revenue growth and a large one-off earnings uplift have reinforced the bull case that MetLife is generating excess capital faster than the market expected, though debate persists over the sustainability of that earnings jump and the interest-rate sensitivity embedded in its spread-based businesses.

People also watch

Aflac

Aflac

AFL

Analysis
Prudential Financial

Prudential Financial

PRU

Analysis
Unum

Unum

UNM

Analysis
Globe Life

Globe Life

GL

Analysis
Jackson Financial Inc.

Jackson Financial Inc.

JXN

Analysis

BobbyInvestment Opinion: Should I buy MET Today?

Rating: Buy (constructive, moderate conviction). The core thesis is that MetLife has transformed from a cheap-for-a-reason life insurer into a capital-return compounder: 21.57% YoY revenue growth, a Q3 2026 net margin of 11.68%, a 9.18x forward PE on $13.29 consensus EPS, and a 3.24% dividend yield paired with aggressive buybacks (shares down from 664.96 million in Q4 2025 to 635 million in Q3 2026) form a coherent per-share value-creation story. The analyst consensus of 13 Buy, 4 Hold, and 1 Sell with a recommendation mean of 1.89 and an average target of $110.94 (8.1% upside) supports a positive but not urgent stance.

The supporting evidence is broad. Valuation is the anchor: 9.18x forward earnings versus a 16.45x trailing multiple implies a 44% earnings-growth discount, while 0.68x price-to-sales and 1.07x EV-to-sales are low in absolute terms and 7.82x EV/EBITDA is reasonable for a capital-intensive insurer. Growth is accelerating — revenue rose from $18.88 billion in Q2 2026 to $20.52 billion in Q3 2026, up 21.57% from $16.88 billion a year earlier. Profitability is improving but lumpy: Q3 net income of $2.397 billion ($3.70 EPS) versus $736 million ($1.10) in Q2 and $1.185 billion ($1.75) in Q1, with the quarterly net margin swinging from 3.90% to 11.68%. Cash generation and returns are strong: $15.0 billion trailing free cash flow, $2.0 billion of Q3 operating cash flow funding $425 million of dividends and $651 million of buybacks, a 50.4% payout ratio, and an 11.90% ROE, all against a manageable 0.71 debt-to-equity.

The biggest risks that could invalidate the thesis are (1) earnings quality — if the Q3 uplift was driven by reserve releases or investment gains rather than a new baseline, the $13.29 forward EPS is unreachable and the 9.18x multiple is illusory; (2) rate sensitivity — roughly 52% of adjusted earnings come from spread-based U.S. businesses, so falling rates would compress spread income; and (3) valuation — 1.85x P/B sits in the upper portion of a multi-year band that ran from 1.64x at year-end 2023 to 2.69x in Q3 2026, and at $102.65 the stock is only 3.9% below its $106.72 52-week high with just 8.1% average-target upside. This Buy would upgrade to a high-conviction Buy if Q4 2026 confirms EPS near the $13.29 consensus and the stock breaks above $106.72; it would downgrade to Hold if quarterly net margin falls back below 6% or revenue growth decelerates below 10%. Verdict: fairly valued to modestly undervalued on forward earnings, but no longer cheap on book — the stock is priced for delivery, not for re-rating.

Sign up to view all

MET 12-Month Price Forecast

The forward-looking case is constructive but not asymmetric: MetLife trades at 9.18x forward earnings on a $13.29 consensus EPS, a 44% discount to its 16.45x trailing multiple, while revenue is accelerating at 21.57% YoY and management is shrinking the share count from 664.96 million to 635 million. The central uncertainty is earnings quality — quarterly net margin swung from 3.90% in Q2 2026 to 11.68% in Q3, so the forward multiple is only as real as the consensus EPS behind it. Analyst sentiment is supportive (13 Buy, 4 Hold, 1 Sell; $110.94 average target) but the 8.1% implied upside and 56% target spread ($84.00-$131.00) show conviction is maintenance rather than momentum. With a 0.773 beta and 29.17% one-year outperformance versus the S&P 500's 12.27%, the risk/reward favors a constructive Buy sized moderately rather than aggressive accumulation near the $106.72 52-week high. I would upgrade to high confidence if Q4 2026 confirms EPS near $13.29 with net margin above 10%, and downgrade to neutral if quarterly net margin falls below 6% or revenue growth decelerates below 10%.

Historical Price
Current Price $95.67
Average Target $108.00
High Target $131.00
Low Target $84.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on MetLife's 12-month outlook, with a consensus price target around $111.13 and implied upside of +16.1% versus the current price.

Average Target

$111.13

18 analysts

Implied Upside

+16.1%

vs. current price

Analyst Count

18

covering this stock

Price Range

$84 - $131

Analyst target range

Buy
13 (72%)
Hold
4 (22%)
Sell
1 (6%)

Coverage is robust, with 16 analysts following MetLife and a distribution of 13 Buy, 4 Hold, and 1 Sell, yielding a consensus recommendation of "buy" and a recommendation mean of 1.89 (where 1.0 is a strong buy). The average target price of $110.94 implies roughly 8.1% upside from the current $102.65, a moderate but positive signal that suggests the Street sees the stock as fairly valued with room for continued appreciation rather than deeply undervalued. The bullish tilt is notable given the stock's 29% one-year run, indicating analysts believe the fundamental momentum can persist.

The target range spans $84.00 to $131.00 — a wide 56% spread that signals meaningful dispersion in outlooks. The high target of $131.00 (27.6% above current) likely assumes continued earnings beats, further multiple expansion toward book-value-plus-growth frameworks, and successful capital deployment through buybacks; the low target of $84.00 (18.2% below current) would price in margin compression, adverse rate moves, or a reversion to the sector's historical discount. Institutional ratings show a clear pattern of reaffirmation rather than revision — Wells Fargo, Mizuho, Piper Sandler, TD Cowen, JPMorgan, Barclays, and UBS all maintained Overweight/Buy/Outperform ratings between October 5 and November 12, 2026, with no downgrades — suggesting stable conviction and a supportive analyst backdrop, though the absence of fresh upgrades means the consensus is more maintenance than momentum.

Drowning in data?

Find the real signal!

Bulls vs Bears: MET Investment Factors

The bull case currently has stronger evidence: 21.57% revenue growth, a Q3 net margin of 11.68%, a 9.18x forward PE, and a 3.24% dividend yield with aggressive buybacks form a coherent capital-compounder story, and analysts are 13 Buy to 4 Hold and 1 Sell with an $110.94 average target. The bear case rests less on fundamentals than on positioning and quality of earnings — the stock is 3.9% from its 52-week high with only 8.1% implied upside, and the Q3 profit surge looks partly one-off given the swing from $1.10 to $3.70 in quarterly EPS. The single most important tension is whether the Q3 earnings uplift represents a new baseline or an outlier: if MetLife can sustain EPS near the $13.29 consensus, the 9.18x forward multiple is cheap and the stock re-rates further; if Q3 was inflated by reserve releases or investment gains, the forward multiple is an illusion and the 1.85x P/B premium is vulnerable. With a 0.773 beta and 29% one-year outperformance, the risk/reward is favorable but no longer asymmetric, favoring a constructive Hold-to-Buy stance rather than aggressive accumulation at current levels.

Bullish

  • Forward PE of 9.18x is deeply discounted: At $102.65, MET trades at just 9.18x forward EPS of $13.29 versus a 16.45x trailing multiple, a 44% compression that implies the market expects earnings to roughly double. Even against a 1.85x price-to-book, the earnings-based valuation leaves substantial room for re-rating if the Street's $13.29 EPS estimate is delivered.
  • Revenue accelerating at 21.6% YoY: Q3 2026 revenue of $20.52 billion grew 21.57% over Q3 2025's $16.88 billion, and the sequential trend shows acceleration from $19.07 billion in Q1 and $18.88 billion in Q2. This is well above the typical low-single-digit growth for a mature life insurer and supports the capital-compounder narrative.
  • Q3 margin surge to 11.68% net: Net income of $2.397 billion and EPS of $3.70 in Q3 2026 dwarfed Q2's $736 million ($1.10) and Q1's $1.185 billion ($1.75), lifting the quarterly net margin to 11.68% from 3.90% and 6.21%. Gross margin also expanded to 33.59%, though the volatility of this line argues for caution in extrapolating.
  • Aggressive capital return with 3.24% yield: MetLife paid $425 million in dividends and repurchased $651 million of stock in Q3 2026 alone, funded by $2.0 billion of operating cash flow, while the 50.4% payout ratio leaves room for increases. The 3.24% dividend yield plus a shrinking share count (635 million shares in Q3 versus 664.96 million in Q4 2025) compounds per-share value.

Bearish

  • Near 52-week high with limited upside: At $102.65, MET sits at roughly 89.6% of its $67.33-$106.72 annual range, just 3.9% below the 52-week high, while the average analyst target of $110.94 implies only 8.1% upside. Much of the improving fundamental story appears already priced in, leaving a thin margin of safety.
  • Earnings quality is volatile and lumpy: Quarterly net margins swung from 3.90% in Q2 2026 to 11.68% in Q3, and the Q3 EPS of $3.70 versus $1.10 the prior quarter suggests a large one-off item, likely favorable investment results or reserve releases. If that uplift does not repeat, the trailing 16.45x PE is misleading and the forward 9.18x multiple rests on an aggressive $13.29 consensus EPS.
  • Price-to-book at multi-year highs: MET's P/B has climbed from 1.64x at year-end 2023 to 2.69x in Q3 2026, and the current 1.85x sits in the upper portion of its multi-year band. Further multiple expansion is limited, meaning forward returns must come from earnings delivery rather than re-rating, and any disappointment could compress the premium.
  • Thin absolute profitability and rate sensitivity: Trailing net margin of 4.38% and operating margin of 6.05% are thin, and roughly 52% of adjusted earnings come from spread-based U.S. businesses (Group Benefits and RIS) that are sensitive to interest-rate moves. A decline in rates would pressure spread income and could reverse the earnings momentum that drove the re-rating.

MET Technical Analysis

MetLife is in a sustained, well-established uptrend, with the stock up 29.17% over the past year and 27.80% year-to-date, dramatically outperforming the S&P 500's 12.27% and 10.62% respective gains. At a current price of $102.65, the stock sits at roughly 89.6% of its 52-week range of $67.33 to $106.72, positioning it near the upper end of its annual band — a sign of persistent momentum rather than a value opportunity, though it has not yet broken out to fresh highs. This positioning implies the market has already priced in a substantial portion of the improving fundamental story, leaving less margin of safety for disappointment.

Short-term momentum is positive but decelerating relative to the longer-term trend: the stock is up 2.94% over the past month and 5.11% over three months, versus the 29.17% one-year gain, indicating the pace of appreciation has cooled as the stock consolidates below its highs. Notably, this modest recent performance still represents meaningful relative strength, with MET beating the S&P 500 by 5.20 percentage points over one month and 7.94 points over three months while the index itself declined 2.26% and 2.83% respectively — a hallmark of defensive leadership in a weak tape. The 6-month gain of 28.67% (versus SPY's 2.13%) confirms the rally was front-loaded earlier in the year, and the current consolidation looks like healthy digestion rather than distribution, though the absence of volume data limits confirmation.

Key technical levels are well defined: support sits near the 52-week low of $67.33, with intermediate support likely around the $94-$96 shelf that held repeatedly through August and September, while resistance is anchored at the 52-week high of $106.72, just 3.9% above the current price. A breakout above $106.72 would signal a continuation of the primary uptrend and likely invite momentum-driven buying, whereas a breakdown below the $94 support zone would mark a trend change and expose the mid-$80s. With a beta of just 0.773, MetLife is roughly 23% less volatile than the market, meaning its 29% one-year gain was achieved with below-market risk — an attractive risk-adjusted profile that supports larger position sizing, though the low beta also implies the stock will lag in a sharp risk-on rally.

Beta

0.77

0.77x market volatility

Max Drawdown

-18.1%

Largest decline past year

52-Week Range

$67-$107

Price range past year

Annual Return

+29.4%

Cumulative gain past year

PeriodMET ReturnS&P 500
1m-6.4%-9.7%
3m+1.4%-9.9%
6m+13.8%-7.5%
1y+29.4%+4.7%
ytd+19.1%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

MET Fundamental Analysis

Revenue is growing robustly, with Q3 2026 revenue of $20.52 billion representing 21.57% year-over-year growth versus Q3 2025's $16.88 billion, and the multi-quarter trend shows acceleration: revenue rose from $18.88 billion in Q2 2026 and $19.07 billion in Q1 2026, up from $17.18 billion and $18.26 billion in the comparable 2025 quarters. The Q3 2026 figure also exceeds Q4 2025's $23.81 billion seasonal peak on a sequential basis when adjusted for the typical fourth-quarter spike, and the segment mix — with fee-based investment management ($187 million), administrative services ($81 million), and prepaid legal/vision contracts contributing recurring fee streams — supports a durable, less rate-sensitive revenue base alongside spread income. This growth trajectory, if sustained, underpins the re-rating case, though investors should note insurance revenue can be inflated by investment gains and reserve adjustments rather than purely organic premium growth.

Profitability improved sharply in Q3 2026, with net income of $2.397 billion and EPS of $3.70, a dramatic jump from Q2 2026's $736 million ($1.10 EPS) and Q1 2026's $1.185 billion ($1.75 EPS); the Q3 net margin of 11.68% compares favorably to Q2's 3.90% and Q1's 6.21%, and gross margin expanded to 33.59% from 14.76% in Q2 and 37.24% in Q1. The trailing net margin of 4.38% and operating margin of 6.05% remain thin by absolute standards but are typical for life insurers, where profitability is driven by spread income and underwriting rather than high-margin product sales; the Q3 surge likely reflects favorable investment results, reserve releases, or a one-time item that may not repeat. The key question is whether the 11.68% quarterly margin represents a new baseline or an outlier — the volatile quarterly pattern (3.90% to 11.68%) argues for caution in extrapolating.

Financial health is solid: debt-to-equity stands at 0.71, ROE is 11.90%, and the company generated $15.0 billion in trailing free cash flow against a $52.5 billion market cap, implying an FCF yield of roughly 28.6% — extraordinarily high, though for insurers this metric is distorted by investment portfolio cash flows and should be read alongside the $19.79 billion cash balance. The current ratio of 0.65 reflects the insurance business model rather than liquidity stress, and the company returned capital aggressively in Q3 2026 alone, paying $425 million in dividends and repurchasing $651 million of stock, funded comfortably by $2.0 billion in operating cash flow. With interest coverage healthy and a payout ratio of 50.4%, MetLife generates ample internal cash to fund both growth and shareholder returns without external financing dependence.

Quarterly Revenue

$20.5B

2026-09

Revenue YoY Growth

+21.6%

YoY Comparison

Gross Margin

33.6%

Latest Quarter

Free Cash Flow

$15.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Administrative Service
Distribution Service
Fee-based investment management services
Other revenue from service contracts from customers
Prepaid legal plans and administrative-only contracts
Vision fee for service arrangements

Open an Account, get $2 TSLA now!

Valuation Analysis: Is MET Overvalued?

Because MetLife is solidly profitable (Q3 2026 net income of $2.397 billion), the PE ratio is the appropriate primary metric. The stock trades at a trailing PE of 16.45x but a forward PE of just 9.18x — a striking 44% compression that implies the market expects earnings to roughly double, consistent with the consensus EPS estimate of $13.29 versus the trailing figure distorted by the low reported EPS of $0.06 (likely a data artifact from a specific share-class or adjusted calculation). The forward multiple of 9.18x is the more economically meaningful figure and sits well below the broader market, reflecting the persistent insurance-sector discount.

Against the life insurance industry, MetLife's 9.18x forward PE and 1.85x price-to-book represent a modest premium to book but a discount on earnings, while its 0.68x price-to-sales and 1.07x EV-to-sales are low in absolute terms; the 7.82x EV/EBITDA is reasonable for a capital-intensive insurer. The 3.24% dividend yield is a meaningful component of total return and exceeds the sector norm, and the 50.4% payout ratio leaves room for continued increases. On balance, the valuation does not appear stretched relative to the company's 11.90% ROE and improving earnings trajectory, though the premium to book (1.85x) is at the higher end of its recent history.

Historically, MetLife's PE has ranged widely — from 6.36x in Q3 2026 and 10.10x in Q1 2026 to over 19x in mid-2025 and 28x in 2023 — while its price-to-book has climbed from 1.64x at year-end 2023 to 2.69x in Q3 2026, near the top of its multi-year band. The current 1.85x P/B and 16.45x trailing PE sit in the middle-to-upper portion of this range, suggesting the market has already re-rated the stock substantially and is pricing in optimistic but not euphoric expectations. The risk is that further multiple expansion is limited, making earnings delivery — not re-rating — the primary driver of forward returns.

PE

16.4x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 6x~29x

vs. Industry Avg

11.7x

Industry PE ~11.7x*

EV/EBITDA

7.8x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on earnings quality and rate sensitivity. Quarterly net income swung from $736 million in Q2 2026 to $2.397 billion in Q3, and the net margin ranged from 3.90% to 11.68%, indicating that a meaningful portion of the Q3 beat likely came from favorable investment results or reserve releases that may not recur. Roughly 52% of adjusted earnings derive from spread-based U.S. businesses (Group Benefits and RIS), so a decline in interest rates would directly compress spread income, while the thin trailing net margin of 4.38% and operating margin of 6.05% leave little buffer. Debt-to-equity of 0.71 and a current ratio of 0.65 are manageable for an insurer but reflect a leveraged, capital-intensive balance sheet where a $15.0 billion trailing FCF figure is distorted by investment-portfolio cash flows rather than pure operating generation.

Market and competitive risks are dominated by valuation compression and sector rotation. MET's P/B has risen from 1.64x at year-end 2023 to 2.69x in Q3 2026, and the current 1.85x sits in the upper portion of its multi-year band, so further multiple expansion is unlikely and any earnings miss could trigger a de-rating toward the sector's historical discount. The stock's 29.17% one-year gain versus the S&P 500's 12.27% means it now carries momentum-investor ownership that could unwind quickly, and with a beta of 0.773 it will lag in a sharp risk-on rotation away from defensives. The wide $84.00-$131.00 analyst target range (a 56% spread) underscores that conviction on the earnings trajectory is not uniform, and the absence of fresh upgrades since October 2026 suggests the consensus is maintenance rather than momentum.

The worst-case scenario is a combination of a rate-driven spread-income squeeze, non-recurrence of the Q3 earnings uplift, and a rotation out of defensive financials. In that chain, forward EPS would fall well short of the $13.29 consensus, the 9.18x forward multiple would prove illusory, and the stock would revert toward its historical P/B band and the analyst low target of $84.00 — an 18.2% decline from $102.65. A deeper drawdown toward the 52-week low of $67.33 would represent a 34.4% loss, consistent with the stock's historical max drawdown of -18.33% being exceeded in a genuine earnings-reset scenario. Realistically, investors should underwrite a -18% to -34% downside range in the adverse case, with the $94-$96 technical shelf as the first warning level and a break below it exposing the mid-$80s.

FAQ

The most severe risk is earnings quality: quarterly net margin swung from 3.90% in Q2 2026 to 11.68% in Q3, and EPS jumped from $1.10 to $3.70, suggesting reserve releases or investment gains that may not recur — if so, the $13.29 consensus EPS is unreachable. Second is rate sensitivity: roughly 52% of adjusted earnings come from spread-based U.S. Group Benefits and RIS, so falling rates would compress the income underpinning the thesis. Third is valuation compression: at 1.85x P/B near the top of its multi-year band and 3.9% below the 52-week high, further multiple expansion is limited and any miss could de-rate the stock toward the $84.00 low target. Fourth is positioning and rotation: the 29.17% one-year gain has attracted momentum ownership that could unwind quickly in a risk-on rotation away from defensives, with a 0.773 beta meaning it will lag in sharp rallies.

The base case carries 55% probability with a $105-$111 target range, assuming forward EPS lands near the $13.29 consensus, rates stay roughly flat, and buybacks continue at the current pace — this aligns with the $110.94 analyst average. The bull case at 25% probability targets $120-$131, requiring Q4 2026 to confirm the Q3 earnings surge as a new baseline, net margin above 10%, and a breakout above $106.72 toward the $131.00 high target. The bear case at 20% probability targets $84-$94, driven by a rate-driven spread-income squeeze and non-recurrence of the Q3 uplift, with the $94-$96 technical shelf breaking first. The base case is most likely because it requires only maintenance of current trends rather than acceleration, and its key assumption is that Q3's $3.70 EPS was partly non-recurring but still leaves earnings solidly above 2025 levels.

The answer depends on which metric you weight. On earnings, MET looks undervalued: 9.18x forward PE versus 16.45x trailing implies a 44% compression, and 0.68x price-to-sales and 1.07x EV-to-sales are low in absolute terms, with 7.82x EV/EBITDA reasonable for a capital-intensive insurer. On book value, it looks closer to fairly valued to modestly rich: 1.85x P/B sits in the upper portion of a band that ran from 1.64x at year-end 2023 to 2.69x in Q3 2026. The market is therefore pricing in delivery of the $13.29 consensus EPS rather than granting a re-rating — if earnings land, the forward multiple is cheap; if Q3's $3.70 EPS proves partly one-off, the earnings-based discount is illusory and the book premium is exposed.

From a risk/reward standpoint, MET offers a favorable but no longer asymmetric setup. The stock trades at 9.18x forward EPS of $13.29 against a 16.45x trailing multiple, pays a 3.24% dividend, and has 13 Buy ratings versus 4 Hold and 1 Sell, with an average target of $110.94 implying 8.1% upside. The downside case is real: the analyst low target of $84.00 sits 18.2% below the current $102.65, and a full reversion toward the $67.33 52-week low would mean a 34.4% loss. It is a good buy for income-oriented, risk-conscious investors with a 12-month-plus horizon who can tolerate earnings-quality uncertainty, particularly on pullbacks toward the $94-$96 support shelf; it is less compelling for momentum traders buying within 3.9% of the 52-week high with limited near-term upside.

MET is better suited to medium-to-long-term holding than short-term trading. It is a mature, capital-return compounder — buybacks shrank shares from 664.96 million to 635 million over four quarters while the 3.24% dividend and 50.4% payout ratio provide steady income — and its 0.773 beta means it lacks the volatility that short-term traders exploit. Earnings visibility is moderate rather than high given the quarterly margin swing from 3.90% to 11.68%, so near-term catalysts are limited to Q4 2026 results and the $106.72 breakout level. A minimum holding period of 12-18 months is appropriate to capture at least one full earnings cycle confirming or refuting the $13.29 consensus, plus the dividend and buyback compounding; short-term traders should instead watch the $94-$96 support and $106.72 resistance as defined entry and exit levels.